Ensysce Biosciences Inc ENSC.OQ ENSC.O is expected to show a rise in quarterly revenue when it reports results on August 12 (estimated) for the period ending June 30 2025
The La Jolla California-based company is expected to report a 257.5% increase in revenue to $650 thousand from $181.8 thousand a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Ensysce Biosciences Inc is for a loss of $1.18 per share.
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Ensysce Biosciences Inc is $26.23, about 92.1% above its last closing price of $2.08
This summary was machine generated August 8 at 13:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)